Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries C4 Therapeutics, Inc. - Common Stock (NQ: CCCC ) 6.860 -0.520 (-7.05%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 3,313,543 Open 7.450 Bid (Size) 6.860 (20) Ask (Size) 7.010 (1) Prev. Close 7.380 Today's Range 6.575 - 7.525 52wk Range 1.060 - 11.88 Shares Outstanding 48,797,226 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 July 16, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day July 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Performance YTD +5.21% +5.21% 1 Month +65.70% +65.70% 3 Month +0.44% +0.44% 6 Month +0.15% +0.15% 1 Year +99.42% +99.42% More News Read More C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors June 10, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Key Takeaways From C4 Therapeutics Analyst Ratings May 09, 2024 Via Benzinga Breaking Down C4 Therapeutics: 4 Analysts Share Their Views February 26, 2024 Via Benzinga Analyst Expectations For C4 Therapeutics's Future January 29, 2024 Via Benzinga C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain January 10, 2024 Via Investor Brand Network CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 29, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum April 09, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 April 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 March 05, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins March 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 22, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session February 20, 2024 Via Benzinga Topics Stocks Exposures US Equities 7 Exciting Stocks Poised for Explosive Growth in Key Sectors January 22, 2024 Via InvestorPlace C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines January 09, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals January 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire MarketBeat Week in Review – 12/18 - 12/22 December 23, 2023 Via MarketBeat Topics Economy Exposures Interest Rates C4 Therapeutics blasts off: what's next? December 18, 2023 Via MarketBeat Topics ETFs C4 Therapeutics Inc. (NASDAQ: CCCC) Near Top of Volume Charts in Friday Trading December 15, 2023 Via Investor Brand Network What's Going On With C4 Therapeutics Stock? December 15, 2023 Via Benzinga Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet December 15, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.